Osteoporosis & Bone Health

About This Condition

Osteoporosis affects over 10 million Americans, with an additional 44 million having low bone density (osteopenia). It is a silent disease until fracture — and hip fractures in particular carry a one-year mortality rate of 20–30%. Despite this severity, bone health receives almost no attention in primary care until a fracture occurs or a DXA scan returns flagged results. The drivers of bone loss are multifactorial: estrogen and testosterone decline, vitamin D and K2 deficiency, calcium metabolism dysregulation, inadequate dietary protein, physical inactivity (particularly absence of impact and resistance loading), proton pump inhibitor use (impairing calcium absorption), and corticosteroid exposure.

Our Approach

We perform bone density assessment using our iDXA scanner — the same device used in research settings — providing trabecular bone score (TBS) alongside standard DEXA measurements, giving a superior assessment of bone quality beyond just density. Our bone health workup includes 25-OH vitamin D, vitamin K1 and K2 status, PTH, calcium, phosphorus, sex hormones, serum protein and albumin, and when indicated, bone turnover markers (CTX, P1NP). Treatment protocols include optimized vitamin D3 + K2 MK-7 dosing, calcium optimization (dietary-first), sex hormone optimization (particularly in peri/postmenopausal women), and a structured progressive resistance and impact loading exercise prescription. We co-manage with endocrinology or rheumatology for patients who require pharmacologic bone therapy (bisphosphonates, denosumab, teriparatide) and monitor response with serial iDXA.